Development of AVID200, a novel TGF-β targeting immunotherapy: Characterization of immunomodulatory effects. (December 2016) - O'Connor-McCourt, M.; Lenferink, A.; Zwaagstra, J.; Sulea, T.; Weeratna, R.; Maleki, S.; Baardsnes, J.; Collins, C.; Cantin, C.; Durocher, Y.; Singh, R.; Figueredo, R.; et al.